Dedifferentiated Liposarcoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Dedifferentiated Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions.
Dedifferentiated liposarcoma (DDLPS) is a rare and aggressive type of cancer that arises from fat cells. It usually occurs in the limbs or the abdomen, and can cause pain, swelling, or a lump under the skin. DDLPS is a subtype of liposarcoma that develops from a low-grade tumor called well-differentiated liposarcoma (WDLS). The tumor undergoes a transformation to a high-grade sarcoma that is typically not lipogenic, meaning it does not produce fat. DDLPS is characterized by genetic changes involving the 12q13-15 region, which leads to the overexpression of several genes, including MDM2. DDLPS has a high risk of recurrence and metastasis, and requires surgery, radiation therapy, and chemotherapy for treatment. The prognosis of DDLPS depends on the location, size, and grade of the tumor, as well as the extent of surgical resection.
The Dedifferentiated Liposarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Dedifferentiated Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dedifferentiated Liposarcoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Dedifferentiated Liposarcoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 31 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Dedifferentiated Liposarcoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Dedifferentiated Liposarcoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Dedifferentiated Liposarcoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAkeso Inc
ANTUREC Pharmaceuticals GmbH
Astex Pharmaceuticals Inc
AstraZeneca Plc
BeiGene Ltd
BioInvent International AB
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CoBioRes NV
Eli Lilly and Co
Eucure (Beijing) Biopharma Co Ltd
Immutep Ltd
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Novartis AG
OncoResponse Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
Sanofi
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Dedifferentiated Liposarcoma reports